Drug intelligence / Profile preview

Restora

Development stage: Discontinued
Modality: Small Molecules
Administration: Topical

Overview

Restora is a non-absorbable, steroid-eluting spacer designed for use after endoscopic sinus surgery (ESS). It is intended to improve healing and prevent the formation of middle meatus synechiae, a common complication of ESS. The device delivers approximately 370 µg of Mometasone Furoate, a corticosteroid, locally to the surgical site over a period of 6-8 days to reduce inflammation and promote proper healing.

Brand names: Restora

Targets

GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on Restora.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Restora.

Explore the full profile